Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Palantirs Q3 earnings and guidance are the dominant focus, with traders debating whether results can clear a high bar as AI stocks face a broader repricing. Bulls expect continued growth and an outlook increase, while bears argue that even a beat may not support the valuation without stronger guidance.

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

Anticipation of QUILT-2.005 Phase 3 results for ANKTIVA plus BCG in BCG-nave bladder cancer dominates discussion, alongside hopes that quarterly results will show continued commercial growth. Many traders see the data as a potential path to broader use after ANKTIVAs expanded bladder-cancer approval, while others question the efficacy outlook and competition; short-squeeze claims remain speculative.

Hyperliquids rally and repeated tests of record levels have traders focused on a push toward the $100 mark. Bulls point to fee-funded HYPE buybacks and growing institutional or regulated-market access as support for the tokens market story, while others warn of pullbacks and selling pressure.

Agenuss BOT+BAL immunotherapy data presented at ESMO, including early neoadjuvant colon cancer responses and sarcoma activity, are driving discussion. Bulls view the findings as promising validation, while skeptics point to small, nonrandomized studies and ongoing concerns about execution and dilution.

Zevra is drawing attention around its Q3 results and the pending CHMP re-examination of MIPLYFFA for Niemann-Pick type C, with FDA feedback on celiprolol also viewed as a potential catalyst. Traders are weighing confidence in U.S. commercial growth against skepticism about a favorable European regulatory outcome and concerns about management execution.

IBB is drawing attention amid a biotech-sector rebound and perceived rotation from technology and semiconductors into healthcare; traders highlight the ETFs resilience near highs, while some caution that the rally may pause and smaller biotech names remain more volatile.

Rubriks shares are under pressure after strong quarterly results and a higher full-year outlook, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance following a sharp pre-earnings run. Some view the selloff as profit-taking and a buying opportunity, while others argue expectations and valuation had become too high.

A stronger-than-expected Q3 report and raised full-year outlook are supporting bullish attention, alongside Mercks Moderna-partnered melanoma vaccine meeting Phase 3 endpoints with Keytruda. Traders see potential oncology-platform value, but debate whether the results meet high expectations and how much upside the vaccine may add for Merck.